Related Experiment Videos

The 2018 landscape of RA, PsA, and SpA pathogenesis

¹Department of Medicine, Division of Rheumatology and Psoriatic Arthritis Center, New York University School of Medicine and Hospital for Joint Diseases, New York, New York, USA.

Current Opinion in Rheumatology

|October 17, 2017

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.

Annals of the rheumatic diseases·2026

Accelerometry-Derived Activity and Sleep Patterns in the NIH All of Us Cohort: Insights and Predictive Potential for Inflammatory Arthritis.

ACR open rheumatology·2026

To the homeRNAmax: Developing an Improved Blood Self-Collection and Stabilization Platform for Remote Transcriptomic Studies.

Analytical chemistry·2026

Multi-cohort Analysis Reveals Microbiome Signatures Associated with Drug Response in New-Onset Rheumatoid Arthritis.

bioRxiv : the preprint server for biology·2026

Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026

See all related articles